Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT03310541	Phase I	Capivasertib Capivasertib + Enzalutamide Capivasertib + Fulvestrant	AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations	Completed	USA	0
NCT05513703	Phase II	Telisotuzumab vedotin	A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Terminated	USA \| ITA \| ISR \| FRA \| DEU \| AUS	3
NCT05159245	Phase II	Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)	Recruiting	FIN	0
NCT06208124	Phase Ib/II	IMM-6-415	A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors	Recruiting	USA	0
NCT05554328	Phase II	Selumetinib Olaparib + Selumetinib	Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT03665129	Phase I	Avdoralimab + Durvalumab	IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)	Terminated	USA \| FRA	0
NCT02140840	Phase II	Trametinib	A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib	Withdrawn	USA	0
NCT05200481	Phase II	Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib	Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)	Active, not recruiting	FRA	0
NCT01713972	Phase I	Dabrafenib + Pazopanib	Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors	Completed	USA	0
NCT04984811	Phase II	Atezolizumab + NT-I7	NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	USA	0
NCT05111561	Phase I	Binimetinib + ZEN-3694	Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	Suspended	USA	0
NCT04484142	Phase II	Datopotamab deruxtecan	Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)	Active, not recruiting	USA \| NLD \| ITA \| HUN \| FRA \| ESP \| DEU	3
NCT05597800	Phase II	Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Paclitaxel	Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR)	Not yet recruiting	ITA	0
NCT04169841	Phase II	Durvalumab + Olaparib + Tremelimumab	Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR)	Active, not recruiting	FRA	0
NCT01636622	Phase I	Carboplatin + Paclitaxel + Vemurafenib	Study of Vemurafenib, Carboplatin, and Paclitaxel	Completed	USA	0
NCT06284460	Phase Ib/II	ASTX029 ASTX029 + Decitabine and Cedazuridine	Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms	Withdrawn	USA	0
NCT02285439	Phase Ib/II	Binimetinib	Study of MEK162 for Children With Low-Grade Gliomas	Active, not recruiting	USA	0
NCT05671510	Phase III	ONC-392 Docetaxel	ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)	Recruiting	USA \| TUR \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	2
NCT05555732	Phase III	Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab	Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	8
NCT02367859	Phase II	Dabrafenib + Trametinib	Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma	Completed	USA	0
NCT04222972	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pralsetinib Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)	Active, not recruiting	USA \| TUR \| SWE \| POL \| NOR \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BEL \| AUS \| ARG	6
NCT04166487	Phase II	Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium	Plasma-Adapted First-Line Pembro In NSCLC	Active, not recruiting	USA	0
NCT04526691	Phase I	Cisplatin + Datopotamab deruxtecan + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab deruxtecan + Pembrolizumab	Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)	Active, not recruiting	USA \| ITA \| ESP	2
NCT01596140	Phase I	Temsirolimus + Vemurafenib Everolimus + Vemurafenib	Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer	Completed	USA	0
NCT06270082	Phase I	IK-595	Study of IK-595 in RAS- or RAF-altered Advanced Tumors	Recruiting	USA	0
NCT05687266	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Durvalumab Cisplatin + Pembrolizumab + Pemetrexed Disodium	Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)	Recruiting	USA \| TUR \| SWE \| POL \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BGR \| AUT	8
NCT04775485	Phase II	Tovorafenib	A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1)	Recruiting	USA \| NLD \| ISR \| GBR \| DNK \| DEU \| CHE \| CAN \| AUS	2
NCT05554380	Phase II	Ipatasertib + Paclitaxel	Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT04467801	Phase II	Ipatasertib Docetaxel + Ipatasertib	Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung)	Recruiting	USA	0
NCT05006794	Phase I	GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716	Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies	Recruiting	USA \| ISR	0
NCT04249843	Phase I	BGB3245	Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors	Recruiting	USA \| AUS	0
NCT06104488	Phase I	RO5126766	A Study of Avutometinib for People With Solid Tumor Cancers	Recruiting	USA	0
NCT04683250	Phase Ib/II	Vepafestinib	Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET))	Recruiting	USA	1
NCT05313009	Phase Ib/II	Sotorasib + TH-4000	Tarlox and Sotorasib in Patients With KRAS G12C Mutations	Terminated	USA	0
NCT06194877	Phase I	BGB3245 + Panitumumab	A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers	Recruiting	USA \| AUS	0
NCT03114319	Phase I	TNO155	Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors	Active, not recruiting	USA \| NLD \| ITA \| ESP \| CAN	4
NCT01586195	Phase II	Vemurafenib	Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E	Terminated	USA	0
NCT05935774	Phase II	Atezolizumab + Trabedersen	OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer	Withdrawn	USA	0
NCT03843775	Phase Ib/II	Binimetinib + Encorafenib	A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers	Completed	USA	0
NCT04265534	Phase II	Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium	KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)	Terminated	USA	0
NCT03516981	Phase II	MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab	A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)	Active, not recruiting	USA \| POL \| ITA \| IRL \| GBR \| ESP \| CHE \| CAN \| AUS	7
NCT04644237	Phase II	Trastuzumab deruxtecan	Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)	Completed	USA \| NLD \| ITA \| FRA \| ESP \| CAN \| AUS	3
NCT03088176	Phase I	Dabrafenib + Talimogene laherparepvec + Trametinib	Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma	Unknown status	USA	0
NCT05541822	Phase II	ABN401	To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation	Recruiting	USA	2
NCT04108026	Phase II	Durvalumab	Immunotherapy in Patient With Poor General Condition (SAVIMMUNE)	Active, not recruiting	FRA	0
NCT06625775	Phase I	BBO-10203 + Trastuzumab BBO-10203	Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)	Recruiting	USA	0
NCT04487106	Phase II	Azacitidine + Trametinib + Venetoclax	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	Completed	USA	0
NCT04811001	Phase II	Dacomitinib Osimertinib	Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND)	Recruiting	ITA	0
NCT01765543	Phase I	Rifampin + Vemurafenib	A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy	Completed	USA \| HRV \| BRA	2
NCT03827850	Phase II	Erdafitinib	FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)	Terminated	DEU	0
NCT03429803	Phase I	Tovorafenib	DAY101 In Gliomas and Other Tumors	Active, not recruiting	USA	0
NCT05566795	Phase III	Tovorafenib	DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)	Recruiting	USA \| SWE \| SVN \| NZL \| NOR \| NLD \| ITA \| ISR \| IRL \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BEL \| AUT \| AUS	2
NCT02587650	Phase II	Ceritinib Capmatinib Regorafenib Entrectinib	Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	Terminated	USA	0
NCT05340621	Phase Ib/II	Binimetinib + OKI-179	NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)	Active, not recruiting	USA	0
NCT04699188	Phase Ib/II	JDQ443 JDQ443 + TNO155 JDQ443 + Tislelizumab + TNO155 JDQ443 + Tislelizumab	Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01)	Active, not recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUS	6
NCT04534283	Phase II	Abemaciclib + LY3214996	A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.	Terminated	USA	0
NCT02949843	Phase II	Nivolumab + Pembrolizumab	Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations	Terminated	USA	0
NCT02012231	Phase Ib/II	PLX8394	Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.	Terminated	USA	0

Profile Name	BRAF act mut
Gene Variant Detail	BRAF act mut (gain of function)
Relevant Treatment Approaches	MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting